mRNA-1893
Phase 2Completed 0 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Zika Virus
Conditions
Zika Virus
Trial Timeline
Jun 7, 2021 → Jul 26, 2024
NCT ID
NCT04917861About mRNA-1893
mRNA-1893 is a phase 2 stage product being developed by Moderna for Zika Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT04917861. Target conditions include Zika Virus.
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04917861 | Phase 2 | Completed |
| NCT04064905 | Phase 1 | Completed |
Competing Products
5 competing products in Zika Virus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1893 | Moderna | Phase 1 | 0 |
| mRNA-1325 | Moderna | Phase 1 | 0 |
| VLA1601 + Placebo | Valneva SE | Phase 1 | 23 |
| VLA1601 + CpG 1018® + 3M-052-AF | Valneva SE | Phase 1 | 23 |
| Zika Virus Immune Globulin (ZIKV-IG) | Emergent BioSolutions | Phase 1 | 19 |